Sunshine Biopharma, Inc. NCM · SBFM
Price alert —
Sign in to get a one-time email the moment SBFM crosses your price. Free accounts included.
Sign in / create a free accountSunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada.
SBFM last traded at $1.7, down 5.6% on the day; that's in the lower part of its 52-week range ($1.7–$23.20). Right now it's dipped below its recent average — a spot where watchers often look for signs the dip is stabilizing.
Earnings reports are the biggest scheduled catalysts to keep an eye on, and after the recent dip, watch whether the price stops making lower lows before assuming the worst is over.
A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.
KC1 lower, -1.14 ATR from EMA21 — no notable pattern
- · KC1 lower stretch — light dip
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
- · Aligned with weak downtrend
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
The model's verdict is “Unknown” and accounting quality screens as Weak. Model estimates only — do your own due diligence.
- ✓ More cash than debt
- ✓ Quick ratio 1.62 (antifragile)
- ✓ Current ratio 4.17 (antifragile)
- ✓ Debt/equity 0.31 (antifragile)
- ⚠ Negative retained earnings
- ⚠ Inventory growing faster than revenue
SBFM is a $4 million company, it moves harder than the market (beta 1.3), and the stock is trading near the bottom of its 52-week range.
Earnings
See more →- Last reported
- 2026-05-13
- EPS (act / est)
- -2.50 / -1.60
- Surprise
- -56.2%
About
Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liv…